Caprock Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Caprock Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,330	Closed	-$260K	–	511
2017 Q4	$260K	Buy	+5,330	New	+$266K	0.05%	341
2017 Q3	–	Sell	-10,000	Closed	-$299K	–	484
2017 Q2	$299K	Buy	+10,000	New	+$247K	0.07%	283
2017 Q1	–	Sell	-23,923	Closed	-$610K	–	383
2016 Q4	$610K	Buy	+23,923	New	+$585K	0.15%	128
2016 Q3	–	Sell	-8,000	Closed	-$308K	–	390
2016 Q2	$308K	Buy	+8,000	New	+$332K	0.08%	210

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Caprock Group's JUNO Position: Q1 2018 in Review

Caprock Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 5,330 shares — an estimated $260K sold.

Caprock Group first reported a position in JUNO in Q2 2016 and held it in 4 quarters. The position peaked at $610K in Q4 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Caprock Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Caprock Group sold 5,330 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $260K.
Caprock Group first reported a position in Juno Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
Caprock Group's Juno Therapeutics, Inc. position peaked at $610K in Q4 2016.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Caprock Group's 13F filing for Q1 2018, filed 23 Apr 2018.